Environmental friendly carrier material for nifedipine as hypertension drug
Authors
Abstract:
Nifedipine is a hypertension drug must be consumed three times a day due to its low oral bioavailability. One way of developing a controlled drug delivery system is making nifedipine microcapsules by using environmentally friendly polymers of polylactic acid and polycaprolactone via the evaporation method using oil-in-water solvents. Polylactic acid and polycaprolactone can be said to be environmentally friendly polymers, because they can be degraded naturally in nature both in the biotic, and abiotic environment, or microorganism. In this study, polylactic acid, Polycaprolactone, and nifedipine were dissolved in dichloromethane solvent; then, an emulsifier was added for the emulsification stage. After passing through the dispersion stage for the process of compaction of the microcapsules by solvent evaporation, the microcapsules were filtered. Microcapsules were characterized using particle size analysis, X-ray diffractometry, and scanning electron microscopy, respectively. The drug release percentage was determined by dissolving microcapsules for 55 hours using a buffer at the potential of hydrogen 1.2 and pH 7.4 as dissolution media. In this study, all variations in the composition of polyblend resulted in a percent efficiency of encapsulation ranging from 78.82%-89.84%, and percent release ranging from 6.80%-39.07%. The composition of 100% polylactic acid produces the highest percent encapsulation efficiency of 89.84% but produces the lowest percentage of drug release at 6.80%. The best composition obtained was polylactic acid: polycaprolactone 1:9 (weight per weight), with a percent release of 39.07% and percent encapsulation of 78.82%. Microcapsule solids produced are approximately 96%. Particle Size of microcapsule ranges at 0.5 μM.
similar resources
Design and synthesizing appropriate carrier for release of dexamethasone as an anticancer drug
Introduction: One of the effective drugs in the treatment of cancer is dexamethasone. Dexamethasone is known as one of the safest glucocorticoid, but there is still side-effects, due to its hydrophobicity and low bioavailability. The purpose of the present study is to design a controlled release carrier for dexamethasone in order to overcome constraints and reduce side effects. Materials and Me...
full textFormulation and In-vitro Evaluation of Tretinoin Microemulsion as a Potential Carrier for Dermal Drug Delivery
In this study, tretinoin microemulsion has been formulated based on phase diagram studies by changing the amounts and proportions of inactive ingredients, such as surfactants, co-surfactants and oils. The effects of these variables have been determined on microemulsion formation, particle size of the dispersed phase and release profile of tretinoin from microemulsion through dialysis membrane. ...
full textFormulation and In-vitro Evaluation of Tretinoin Microemulsion as a Potential Carrier for Dermal Drug Delivery
In this study, tretinoin microemulsion has been formulated based on phase diagram studies by changing the amounts and proportions of inactive ingredients, such as surfactants, co-surfactants and oils. The effects of these variables have been determined on microemulsion formation, particle size of the dispersed phase and release profile of tretinoin from microemulsion through dialysis membrane. ...
full textCyclodextrins as Drug Carrier Molecule: A Review
The cyclodextrins have a wide range of applications in different areas of drug delivery and pharmaceutical industry due to their complexation ability and other versatile characteristics. The most common pharmaceutical application of cyclodextrin is to enhance the solubility, stability, safety and bioavailability of drug molecules. The purpose of this review is to discuss and summarize some of t...
full textMy Resources
Journal title
volume 6 issue 4
pages 523- 536
publication date 2020-10-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023